ArticleJournal of gynecologic oncology2022
Epidemiologic study on gestational trophoblastic diseases in Japan.
Article in Journal of gynecologic oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Clinical experience with de-escalated chemotherapy for a subset of high-risk gestational trophoblastic neoplasia at a single institution.International journal of clinical oncology · 2026Article
- Prevalence, Associated Factors, and Evaluation of Clinical and Biochemical Indices of Gestational Trophoblastic Tumors in Patients Referring to Imam Reza Hospital, Kermanshah: A Five-Year Analytical Study (2017-2022).Health science reports · 2026Article
- Electrochemical biosensors: a novel approach for rapid and cost-effective hCG monitoring in gestational trophoblastic tumours.RSC advances · 2026Review
- Choriocarcinoma Histologically Mimicking Epithelioid Trophoblastic Tumor - A Diagnostic Pitfall in Gestational Trophoblastic Neoplasia.International journal of women's health · 2026Article
- Incidental Intraplacental Choriocarcinoma in the Setting of Intrauterine Fetal Demise.Case reports in obstetrics and gynecology · 2026Article
- Placental Site Trophoblastic Tumor: Two Rare Case Report and Literature Review Within a Decade.Case reports in obstetrics and gynecology · 2026Article
- Downregulation of Chromosome 19 miRNA Cluster and the Tumor-Suppressive Role of miR-517a-3p in Choriocarcinoma.Cancer science · 2025Article
- Treatment Outcomes and Resistance Patterns in Low Risk GTN: A 270-Patient Experience from a Tertiary Center.Reproductive sciences (Thousand Oaks, Calif.) · 2025Article
- Article
- Correlation Between Serum and Urine β-hCG in Gestational Trophoblastic Neoplasia: A Step Toward Non-Invasive Disease Monitoring.International journal of women's health · 2025Article
- Demographics, risk factors associated with malignant progression, and pregnancy outcomes of hydatidiform mole: A retrospective cohort study in Shanghai, China.Frontiers in oncology · 2025Article
- A Cross-Sectional Analysis of the Incidence of Hydatidiform Mole in Colombia.Obstetrics and gynecology international · 2025Article
- Vitamin D receptor expression in hydatidiform mole and gestational trophoblastic neoplasia: A cross-sectional study.Journal of Taibah University Medical Sciences · 2024Article
- Expert Pathology for Gestational Trophoblastic Disease: Towards an International Multidisciplinary Team Meeting.Gynecologic and obstetric investigation · 2024Review
- Predicting Chemotherapy Resistance in Gestational Trophoblastic Neoplasia: Ratio of Neutrophils, Lymphocytes, Monocytes, and Platelets.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Gestational trophoblastic diseases - literature review and atypical case reports.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aims to estimate the population-based incidence of gestational trophoblastic diseases (GTDs) and to identify the characteristics of gestational trophoblastic neoplasia (GTN) in Japan.
methodsThe annual number of GTD and live births from 1974 to 2018 were used to estimate the incidence of GTD. The data of 1,574 GTN cases from 1999 to 2018 were analyzed to identify the characteristics of low-risk GTN, high-risk GTN, placental site trophoblastic tumor (PSTT), and epithelioid trophoblastic tumor (ETT).
resultsThe incidence of hydatidiform mole was 2.02 per 1,000 live births on average which decreased from 1974 to 2008 and increased from 2009 to 2018. The incidence of low-risk GTN, high-risk GTN, PSTT, and ETT was 15.3, 3.5, 0.3, and 0.07 per 100,000 live births, respectively. The estimated incidence of post-molar GTN was 9.8% of molar patients. High-risk GTN was diagnosed more pathologically, had more various kinds of antecedent pregnancies, and had longer intervals after the antecedent pregnancy compared to low-risk GTN. Furthermore, 8.2% of high-risk GTN occurred after the subsequent non-molar pregnancy of hydatidiform mole. The cumulative percentage of developing high-risk GTN after hydatidiform mole reached 89.3% at the 60th month.
conclusionThe incidence of hydatidiform mole, low-risk GTN, high-risk GTN was 2.02 per 1,000 live births, 15.3 per 100,000 live births, and 3.5 per 100,000 live births, respectively. High-risk GTN was diagnosed more pathologically and later after the antecedent pregnancy than low-risk GTN. Following molar patients for five years is needed to improve the mortality of malignant GTN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.